1. Articles in category: Events

    1-16 of 16
    1. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma

      Prognosis for relapsed/refractory high-risk neuroblastoma (HR-NBL) remains poor. Bortezomib, a proteasome inhibitor, has shown preclinical activity against NBL as a single agent and in combination with cytotoxic chemotherapy including irinotecan.

      Eighteen HR-NBL patients with primary refractory (n = 8) or relapsed (n = 10) disease were enrolled in a Phase I study using modified Time To Event Continual Reassessment Method.

      Read Full Article
    2. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      Clin Cancer Res. 2017 Apr 21;:

      Authors: Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson ADJ, Modak S, Cash T, Robinson GW, Motta M, Matano A, Bhansali SG, Dobson JR, Parasuraman S, Chi SN

      Read Full Article
    3. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Cochrane Database Syst Rev. 2017 Apr 21;4:CD010349

      Authors: Kraal KC, van Dalen EC, Tytgat GA, Van Eck-Smit BL

      Abstract BACKGROUND: Patients with newly diagnosed high-risk (HR) neuroblastoma (NBL) still have a poor outcome, despite multi-modality intensive therapy.

      Read Full Article
      Mentions: MIBG
    4. Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567

      Authors: McGinty L, Kolesar J

      Abstract PURPOSE: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.

      Read Full Article
      Mentions: Treatment
    5. Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy

      Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy

      ​WASHINGTON — Among patients with high-risk neuroblastoma, those who had a certain combination of genotypes gained substantial benefit from adding immunotherapy to isotretinoin treatment, while it is uncertain whether those who lacked the combination gained benefit from immunotherapy, according to results from a randomized phase III clinical trial presented here at the AACR Annual Meeting 2017, April 1-5.

      Read Full Article
    6. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

      Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

      Lancet Oncol. 2017 Mar 01;:

      Authors: Ladenstein R, Pötschger U, Pearson AD, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D, SIOP Europe Neuroblastoma Group (SIOPEN)

      Abstract BACKGROUND: High-dose chemotherapy with haemopoietic stem-cell rescue ...

      Read Full Article
      Mentions: SIOPEN MYCN SIOP
    7. Impact of disseminated neuroblastoma cells on the identification of the relapse-seeding clone.

      Impact of disseminated neuroblastoma cells on the identification of the relapse-seeding clone.

      Clin Cancer Res. 2017 Feb 22;:

      Authors: Abbasi MR, Rifatbegovic F, Brunner C, Mann G, Ziegler A, Pötschger U, Crazzolara R, Ussowicz M, Benesch M, Ebetsberger-Dachs G, Chan GC, Jones N, Ladenstein R, Ambros IM, Ambros PF

      Read Full Article
      Mentions: Relapse ATRX
    8. Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue.

      Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue.

      Bone Marrow Transplant. 2017 Jan 09;:

      Authors: Utriainen P, Vatanen A, Toiviainen-Salo S, Saarinen-Pihkala U, Mäkitie O, Jahnukainen K

      Read Full Article
      Mentions: Bone Marrow
    9. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.

      The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.

      J Pediatr Oncol Nurs. 2017 Jan 01;:1043454216680595

      Authors: Secola R, Marachelian A, Cohn SL, Toy B, Neville K, Granger M, Brentlinger A, Martin G

      Read Full Article
    10. Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.

      Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.

      Oncoimmunology. 2016;5(11):e1235108

      Authors: Siebert N, Jensen C, Troschke-Meurer S, Zumpe M, Jüttner M, Ehlert K, Kietz S, Müller I, Lode HN

      Read Full Article
      Mentions: Antibody
    11. The UK Childhood Cancer Conference 2015

      The UK Childhood Cancer Conference 2015

      The UK Childhood Cancer Conference takes place on Friday 15th May this year, in association with Children’s Cancer and Leukaemia Group (CCLG) and Bethany’s Wish.  This fantastic event brings together paediatric oncology researchers, world-leading experts, allied health professionals working in the field of paediatric oncology, support groups, children’s cancer charities and most importantly parents of […]

      Read Full Article
    12. Concert to be held in memory of Jamie Inglis

      Concert to be held in memory of Jamie Inglis

      A CONCERT is being held to honour the life of a York school boy whose brave fight against cancer moved people around the world. Lord Deramore’s Primary School pupil Jamie Inglis died last year after suffering from the aggressive childhood cancer neuroblastoma for half his life. Jamie's bravery and unstinting smile inspired thousands of people to support him in undergoing treatment in Germany and the US.

      Read Full Article
    13. ASCO 2010 & Anr 2010 ~ Survival after neuroblastoma relapse

      Citation: J Clin Oncol 28:15s, 2010 (suppl; abstr 9518)

      Wendy London is the Lead Statistician for neuroblastoma research for the Children’s Oncology Group (COG), and Data Center Statistics Committee Chair for the International Neuroblastoma Risk Group (INRG) project and has recently joined the team at Boston Children’s/Dana-Farber.

      Read Full Article
      Mentions: COG Relapse INRG
    14. MIBG avidity, tandem transplant (Korea), and ch14.18 (Germany) updates

      MIBG avidity, tandem transplant (Korea), and ch14.18 (Germany) updates

      POC39 (p. 211) Neuroblastomas with non-avid I-123 MIBG scan and negative urinary catecholamine secretion: A single institute’s experience

      PL30 (p. 102) Analysis of MIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma. A Children’s Oncology Group (A3973) report

      Korean single and tandem retrospective study 1997 to 2005
      Read Full Article
      Mentions: GPOH COG SIOP
    1-16 of 16
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) Immunotherapy
  4. General Informations in the News

    1. (2 articles) Treatment
  5. Treatments in the News

    1. (1 articles) Refractory
    2. (1 articles) MIBG
    3. (1 articles) Chemotherapy